<DOC>
	<DOCNO>NCT02079636</DOCNO>
	<brief_summary>The main purpose study evaluate safety tolerability abemaciclib combination another anti-cancer drug participant NSCLC advance spread part body ( stage IV ) . The study also investigate body process combination treatment study drug affect body . The study also collect disease-related symptom participant-reported pain related NSCLC .</brief_summary>
	<brief_title>A Study Abemaciclib ( LY2835219 ) Combination With Another Anti-cancer Drug Participants With Lung Cancer ( NSCLC )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<mesh_term>Ramucirumab</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>For Parts : The participant must stage IV nonsmall cell lung cancer ( NSCLC ) . For Part A ( abemaciclib + pemetrexed ) : Nonsquamous subtypes . The participant must receive least one three prior therapy advanced/metastatic NSCLC . For Part B ( abemaciclib + gemcitabine ) : Any subtype . The participant must receive least one three prior therapy advanced/metastatic NSCLC . For Part C ( abemaciclib + ramucirumab ) : Any subtype . The participant must receive least two three prior therapy advanced/metastatic NSCLC . For Part D ( abemaciclib + LY3023414 ) : Any subtype . The participant must receive least two , three prior therapy advanced/metastatic NSCLC . The participant must receive prior treatment phosphoinositide 3kinase ( PI3K ) mammalian target rapamycin ( mTOR ) inhibitor . For Part E ( abemaciclib + pembrolizumab ) : Any subtype . The participant must receive least one three prior therapy advanced/metastatic NSCLC . Have either measureable nonmeasurable disease define Response Evaluation Criteria Solid Tumors ( RECIST v1.1 ) . Have adequate organ function include : Hematologic : Absolute neutrophil count ( ANC ) 1.5 x 109/liter ( L ) , platelets 100 x 109/L , hemoglobin 8 gram/deciliter ( g/dL ) . Hepatic : Bilirubin 1.5 time upper limit normal ( ULN ) , alanine aminotransferase ( ALT ) aspartate transaminase ( AST ) 3.0 time ULN . For participant tumor involvement liver , AST ALT equal ≤5.0 time ULN acceptable . Alkaline phosphatase ≤5.0 time ULN participant tumor involvement bone acceptable . Renal : Serum creatinine 1.5 time ULN . Have performance status ≤1 Eastern Cooperative Oncology Group ( ECOG ) scale . Have discontinue previous therapy cancer ( include chemotherapy , radiotherapy , immunotherapy , investigational therapy ) least 21 day myelosuppressive agent 14 day nonmyelosuppressive agent prior receive study drug , recover acute effect therapy ( treatment relate toxicity resolve baseline ) except residual alopecia . Male female participant reproductive potential must agree use medically approve contraceptive precaution trial 3 4 month ( appropriate ) follow last dose study drug . Have estimate life expectancy ≥12 week . Are able swallow oral medication . Have personal history follow condition : presyncope syncope either unexplained cardiovascular etiology , ventricular arrhythmia ( include limit ventricular tachycardia ventricular fibrillation ) , sudden cardiac arrest . Exception : Participants control atrial fibrillation &gt; 30 day prior study treatment eligible . Parts A , B , D E : Have central nervous system ( CNS ) metastasis development associate neurological change 14 day prior receive study drug . Have history cancer ( except nonmelanoma skin cancer carcinoma insitu cervix breast ) , unless complete remission therapy minimum 3 year . Is pregnant breastfeeding , expect conceive father child within project duration trial , start prescreening screen visit 3 4 month last dose trial treatment ( appropriate ) . Have active bacterial , fungal , and/or know viral infection ( example , human immunodeficiency virus [ HIV ] antibody , hepatitis B surface antigen [ HBSAg ] , hepatitis C antibody ) . Screening required enrollment . Parts A , B , C , E : Have QTc interval &gt; 470 millisecond ( msec ) screen electrocardiogram ( ECG ) . Part D participant QTc interval &gt; 450msec screen ECG . Additional Exclusion Criteria For Part C History evidence cardiovascular risk include follow : History acute coronary syndrome ( include myocardial infarction angina ) , coronary angioplasty , stenting within 6 month prior enrollment . History evidence current ≥Class II congestive heart failure define New York Heart Association . Treatment refractory hypertension define blood pressure systolic &gt; 140 millimeter mercury ( mmHg ) and/or diastolic &gt; 90 mmHg control antihypertensive therapy . Participants intracardiac defibrillator . History evidence CNS disease . Radiographic screen participant without history CNS metastasis require . Radiographically document evidence major vessel invasion encasement cancer . Uncontrolled thromboembolic hemorrhagic disorder . Participants receive daily treatment aspirin &gt; 325mg/day know inhibitor platelet function . History gross hemoptysis within 2 month study entry . Evidence nonhealing wound , ulcer , bone fracture within 28 day prior study entry . Undergone major surgery within 28 day prior first dose study drug subcutaneous venous access device placement within 7 day prior first dose . Additional Exclusion Criteria For Part D Have insulindependent diabetes mellitus history gestational diabetes mellitus . Participants type 2 diabetes mellitus eligible adequate control blood glucose level obtain oral antidiabetic agent document hemoglobin A1c ( HbA1c ) &lt; 7 % . History evidence cardiovascular risk include follow History acute coronary syndrome ( include myocardial infarction angina ) , coronary angioplasty , stenting within 6 month prior enrollment . Additional Exclusion Criteria Part E Received prior monoclonal antibody ( mAb ) within 4 week prior study . Has active autoimmune disease require treatment past 2 year . Has history interstitial lung disease pneumonitis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>